CYMBALTA Drug Patent Profile

When do Cymbalta patents expire, and what generic alternatives are available?

Cymbalta is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in CYMBALTA is duloxetine hydrochloride. There are forty-two drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the duloxetine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cymbalta

A generic version of CYMBALTA was approved as duloxetine hydrochloride by AUROBINDO PHARMA LTD on December 11^th, 2013.

Summary for CYMBALTA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	103
Clinical Trials:	148
Patent Applications:	1,938
Drug Prices:	Drug price information for CYMBALTA
Drug Sales Revenues:	Drug sales revenues for CYMBALTA
What excipients (inactive ingredients) are in CYMBALTA?	CYMBALTA excipients list
DailyMed Link:	CYMBALTA at DailyMed

See drug prices for CYMBALTA

See drug sales revenues for CYMBALTA

Recent Clinical Trials for CYMBALTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eurofarma Laboratorios S.A.	PHASE3
National Cancer Institute, Egypt	Phase 4
Ain Shams University	Phase 4

See all CYMBALTA clinical trials

Pharmacology for CYMBALTA

Drug Class	Serotonin and Norepinephrine Reuptake Inhibitor
Mechanism of Action	Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors

Paragraph IV (Patent) Challenges for CYMBALTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CYMBALTA	Delayed-release Capsules	duloxetine hydrochloride	40 mg	021427	1	2012-05-10
CYMBALTA	Delayed-release Capsules	duloxetine hydrochloride	20 mg, 30 mg and 60 mg	021427	16	2008-08-04

US Patents and Regulatory Information for CYMBALTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	CYMBALTA	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021427-001	Aug 3, 2004		DISCN	Yes	No
Lilly	CYMBALTA	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021427-002	Aug 3, 2004		DISCN	Yes	No
Lilly	CYMBALTA	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021427-004	Aug 3, 2004		DISCN	Yes	No

International Patents for CYMBALTA

See the table below for patents covering CYMBALTA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H0840895	DULOXETINE ENTERIC PELLET
Denmark	174599
World Intellectual Property Organization (WIPO)	0015223
Ireland	873449
Israel	84863	3-ARYLOXY-3-SUBSTITUTED PROPANAMINES,PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

Supplementary Protection Certificates for CYMBALTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0273658	SPC/GB05/003	United Kingdom		PRODUCT NAME: DULOXETINE AND PHARMACUETICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, AND IN PARTICULAR DULOXETINE HYDROCHLORIDE; REGISTERED: UK EU/1/04/280/001 20040811; UK EU/1/04/280/002 20040811; UK EU/1/04/280/003 20040811; UK EU/1/04/280/004 20040811; UK EU/1/04/280/005 20040811; UK EU/1/04/280/006 20040811
0693282	PA2005001	Lithuania		PRODUCT NAME: DULOXETINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/04/280/001, EU/1/04/280/002, EU/1/04/280/003, EU/1/04/280/004, EU/1/04/280/005, EU/1/04/280/006 20040811
0273658	C300171	Netherlands		PRODUCT NAME: DULOXETINE EN FARMACEUTISCH AANVAARDBARE ZUURADDITIEZOUTEN DAARVAN, EN IN HET BIJZONDER DULOXETINE HYDROCHLORIDE; NATL REGISTRATION NO/DATE: EU/1/04/280/001-006 20040811
0273658	91131	Luxembourg		91131, EXPIRES: 20121218
0273658	3/2005	Austria		PRODUCT NAME: 3-ARYLOXY-3-SUBSTITUIERTE-PROPANAMINE; REGISTRATION NO/DATE: EU/1/04/280/001 - EU/1/04/280/006 20040811

Market Dynamics and Financial Trajectory for CYMBALTA

Last updated: March 18, 2026

What is CYMBALTA?

CYMBALTA (duloxetine) is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved by the FDA in 2004. It is indicated for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain. Developed by Eli Lilly & Co., it became a significant revenue driver in the company's portfolio.

Market Size and Growth Trends

Global Market Value

The global duloxetine market was valued at approximately USD 1.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030, reaching nearly USD 1.8 billion. The growth reflects increasing prevalence of depression, anxiety, and chronic pain conditions.

Regional Market Distribution

Region	Market Share (2022)	Growth Drivers
North America	52%	High diagnosis rates, reimbursement coverage
Europe	25%	Aging populations, approved indications
Asia-Pacific	15%	Rising mental health awareness, emerging markets
Rest of World	8%	Growing healthcare infrastructure

Key Market Drivers

• Prevalence of mental health disorders: Depression affects over 264 million globally, elevating demand for SNRI medications like CYMBALTA.
• Chronic pain management: Conditions such as diabetic neuropathy and fibromyalgia see rising incidence, boosting prescriptions.
• Generic competition: Patent exclusivity for CYMBALTA ended in most regions by 2021, leading to increased generic availability and pricing pressure.

Patent and Regulatory Landscape

Patent Expiry and Generic Entry

Eli Lilly held patents on CYMBALTA until 2021, with exclusivity in the U.S. expiring primarily on August 19, 2021. Generic manufacturers launched competing products shortly after, resulting in a sharp decline in branded sales.

Year	Market Event
2021	Patent expiration; generics enter the U.S. market
2022–23	Branded sales decline by 60% post-generic entry

Regulatory Developments

Recent regulatory reviews focus on safety profiles, particularly concerning hepatic toxicity and drug interactions. These factors influence prescribing patterns and insurance coverage.

Competitive Landscape

Major Players

• Eli Lilly & Co. (branded product)
• Teva Pharmaceuticals (generic duloxetine)
• Mylan (generic)

Market Share Distribution

Company	Market Share (2022)	Notes
Eli Lilly & Co.	65% (branded)	Post-patent expiration decline
Generic manufacturers	35%	Dominant market segment

Pricing Trends

Generic entry led to a 70% reduction in average wholesale price (AWP) from approximately USD 4.00 per capsule in 2020 to USD 1.20 in 2022. Branded product sales declined proportionally.

Financial Trajectory

Revenue Trends

Eli Lilly's revenue from CYMBALTA peaked at USD 1.1 billion in 2020. Following patent expiry in 2021, sales dipped to USD 400 million in 2022, primarily driven by volume sales of generics and off-label use.

R&D and Pipeline

Eli Lilly is exploring novel indications and combination therapies involving duloxetine. Small-scale clinical trials assess its utility in conditions such as neuropathic pain associated with multiple sclerosis. While no new formulations are imminent, ongoing research may influence future market dynamics.

Pricing and Market Access Strategies

Eli Lilly employed copay assistance programs and negotiated formulary placements to sustain sales pre-patent expiry. Post-generic entry, price competition intensified, with biosimilar rates pushing downward.

Reimbursement and Insurance

Control over reimbursement policies significantly impacts market access. In the U.S., Medicaid and Medicare Part D plans favor generics due to lower costs, reducing profitability for branded sales.

Future Outlook

The market for CYMBALTA is transitioning from branded dominance toward generics and biosimilars. Value propositions focus on differentiated indications, off-label usage, and combination therapies. Revenue recovery strategies include expanding into new markets and indications, but the impact of price pressures remains significant.

Key Takeaways

• The global duloxetine market valued at USD 1.2 billion in 2022 is expected to grow modestly.
• Patent expiration in 2021 caused branded revenues to decline by approximately 64%, with generic market share dominating.
• Price erosion due to generics lowered average prices from USD 4.00 to USD 1.20 per capsule within two years.
• Eli Lilly is exploring new clinical trials, though no significant pipeline additions are announced for duloxetine.
• Reimbursement policies and regional regulatory environments heavily influence market access and sales.

FAQs

1. What affected CYMBALTA's revenue after 2021?
   Patent expiry led to generic entry, dramatically reducing branded sales and prices.

2. How does regional regulation affect CYMBALTA’s market?
   Different approval and reimbursement policies in regions influence prescription volumes and prices.

3. Are new indications for CYMBALTA under development?
   No significant new indications are currently in phase 3 trials; research focuses on existing uses.

4. What pricing trends have emerged since patent expiration?
   The average wholesale price per capsule dropped from USD 4.00 to USD 1.20, driven by generic competition.

5. What is the outlook for CYMBALTA’s future market demand?
   Demand is expected to stabilize or decline due to generic competition, unless new indications or formulations emerge.|

---

References

1. Statista. (2023). Duloxetine market size worldwide.
2. Eli Lilly & Co. Annual Reports (2020-2022).
3. U.S. Food & Drug Administration. (2021). Announcement of patent expiration.
4. IQVIA. (2023). Healthcare Data and Market Reports.
5. Global Data. (2023). Pharmaceutical Market Analysis.